| " Expediting clinical and translational research via Bayesian instrument development": Corrigendum. Y Jiang, DK Boyle, MJ Bott, JA Wick, Q Yu, BJ Gajewski Sage Publications, 2014 | | 2014 |
| A Bayesian analysis of synchronous distance learning versus matched traditional control in graduate biostatistics courses JA Wick, HW Yeh, BJ Gajewski The American Statistician 71 (2), 137-144, 2017 | 3 | 2017 |
| A Connection Between Baseball and Clinical Trials Found in “Slugging Percentage is Not a Percentage—And Why That Matters” BJ Gajewski, JA Wick, TJ Milling Jr The American Statistician 76 (1), 89-89, 2022 | | 2022 |
| A framework for personalized mammogram screening DP Mudaranthakam, M Park, J Thompson, AM Alsup, R Krebill, LC Hinton, ... Preventive Medicine Reports 23, 101446, 2021 | 1 | 2021 |
| A multicenter pilot study examining the role of circulating tumor cells as a blood-based tumor marker in patients with extensive small-cell lung cancer CH Huang, JA Wick, GS Sittampalam, VS Nirmalanandhan, AK Ganti, ... Frontiers in oncology 4, 271, 2014 | 38 | 2014 |
| A novel evaluation of optimality for randomized controlled trials J Wick, SM Berry, HW Yeh, W Choi, CM Pacheco, C Daley, BJ Gajewski Journal of biopharmaceutical statistics 27 (4), 659-672, 2017 | 8 | 2017 |
| A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies SK Williamson, GA Johnson, HA Maulhardt, KM Moore, DS McMeekin, ... Cancer chemotherapy and pharmacology 75, 1075-1087, 2015 | 68 | 2015 |
| A prenatal group based phone counseling intervention to improve breastfeeding rates and complementary feeding: a randomized, controlled pilot and feasibility trial JS Cauble, A Herman, J Wick, J Goetz, CM Daley, DK Sullivan, HR Hull BMC Pregnancy and Childbirth 21, 1-13, 2021 | 12 | 2021 |
| A study design with conditional, serially assessed co‐primary endpoints: An application to a single‐arm, pilot non‐Hodgkin's lymphoma trial JD Mahnken, JA Wick, BJ Gajewski, MS Mayo Drug Development Research 71 (7), 395-403, 2010 | 1 | 2010 |
| Abstract B12: Macrophage inhibitory cytokine-1 as a potential biomarker for racial disparity in prostate cancer D Karan, S Dubey, J Wick, O Tawfik, G Sonpavde, P VanVeldhuizen Cancer Epidemiology, Biomarkers & Prevention 25 (3_Supplement), B12-B12, 2016 | | 2016 |
| Abstract PS7-44: Energetics and lifestyle in inherited syndromes (ELLIE'S study) LE Nye, K Cruz, S Friedman, D Rose, C Befort, DK Sullivan, ... Cancer Research 81 (4_Supplement), PS7-44-PS7-44, 2021 | | 2021 |
| Accrual prediction program: a web-based clinical trials tool for monitoring and predicting accrual for early-phase cancer studies J Liu, JA Wick, DP Mudaranthakam, Y Jiang, MS Mayo, BJ Gajewski Clinical Trials 16 (6), 657-664, 2019 | 7 | 2019 |
| Acosta, S.; Jernberg, J.; Sanberg, CD; Sanberg, PR; Small, BJ C Gemma, PC Bickford, D Aires, G Rockwell, T Wang, J Frontera, J Wick, ... Biochim Biophys Acta 1822, 522-6, 2012 | | 2012 |
| Assessing the incidence and severity of drug adverse events: a Bayesian hierarchical cumulative logit model J Duan, BJ Gajewski, P Sen, JA Wick Journal of Biopharmaceutical Statistics 34 (2), 276-295, 2024 | 1 | 2024 |
| Association of Novel Apo AI Polymorphisms with HDL Function in South Asian Immigrants S Dodani, M Butler, J Wick ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 30 (11), E243-E243, 2010 | | 2010 |
| Atypical ductal hyperplasia on percutaneous breast biopsy: Scoring system to identify the lowest risk for upgrade AL Amin, OD Winblad, AH Zupon, F Fan, O Tawfik, J Wick, S Hunt, ... | 1 | 2021 |
| Atypical ductal hyperplasia on percutaneous breast biopsy: scoring system to identify the lowest risk for upgrade: low-risk ADH features A Amin, O Winblad, A Zupon, F Fan, O Tawfik, J Wick, S Hunt, J Gatewood, ... Archives of Breast Cancer, 144-151, 2022 | 1 | 2022 |
| Bayesian accrual modeling and prediction in multicenter clinical trials with varying center activation times J Liu, J Wick, Y Jiang, M Mayo, B Gajewski Pharmaceutical statistics 19 (5), 692-709, 2020 | 4 | 2020 |
| Bayesian design for two-arm randomized Phase II clinical trials with endpoints from the exponential family using multiple constraints W Jiang, JA Wick, J He, JD Mahnken, MS Mayo Journal of biopharmaceutical statistics 28 (5), 824-839, 2018 | | 2018 |
| Bayesian EMAX model with a mixture of normal distributions for dose–response in clinical trials F Tang, S Carlson, J Wick, BJ Gajewski Contemporary clinical trials 110, 106571, 2021 | 1 | 2021 |
